Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Eur Radiol. 2022 Jan 31;32(7):4967–4979. doi: 10.1007/s00330-021-08529-x

Fig. 1.

Fig. 1.

Flowchart of study design. Among 108 potentially eligible patients who were referred to PET/MR for cancer staging or restaging, 23 patients included in the study and underwent simultaneous 2-[18F]FDG-PET, DW-MRI scan, and contrast-enhanced MRI. At baseline, 22 simultaneous 2-[18F]FDG-PET, DW-MRI, and contrast-enhanced MRI scans were included. Following the chemotherapy treatment, 43 simultaneous 2-[18F]FDG-PET, DW-MRI, and contrast-enhanced MRI scans were performed on the included patients.

Abbreviations: PET/MR: positron emission tomography/magnetic resonance, 2-[18F]FDG-PET: 2-[18F]fluoro-2-deoxy-D-glucose enhanced positron emission tomography, DW-MRI: Diffusion weighted-magnetic resonance imaging.